Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2025 | A retrospective study of asciminib for R/R Ph+ ALL and LBC-CML

Sabina Chiaretti • 5 Dec 2025
ASH 2025
Acute Lymphoblastic Leukemia Chronic Myeloid Leukemia Leukemia Asciminib

Sabina Chiaretti, MD, PhD, University of Rome, Rome, Italy, comments on a retrospective study examining the efficacy of asciminib for relapsed/refractory (R/R) Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL) and lymphoid blast crisis of chronic myeloid leukemia (LBC-CML). Dr Chiaretti highlights that the study showed an overall survival rate of 69% at one year, and suggests that asciminib could be used to bridge patients to transplantation. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Sabina Chiaretti

Ponatinib plus blinatumomab versus imatinib and chemotherapy in Ph+ ALL: the GIMEMA ALL2820 trial 4:52
Ponatinib plus blinatumomab versus imatinib and chemotherapy in Ph+ ALL: the GIMEMA ALL2820 trial
Sabina Chiaretti • 5 Dec 2025
New frontiers in ALL – MRD for clinical practice
Robin Foà et al. • 29 Sep 2022
ALL over the years
Dieter Hoelzer et al. • 29 Sep 2022
T-cell engagers and treating relapsed ALL
Bijal Shah et al. • 29 Sep 2022

Related Videos

Primary efficacy analysis of TKI and inotuzumab ozogamicin-based therapy for newly diagnosed Ph+ ALL 4:18
Primary efficacy analysis of TKI and inotuzumab ozogamicin-based therapy for newly diagnosed Ph+ ALL
Anand Patel • 25 Nov 2025
Ponatinib plus blinatumomab versus imatinib and chemotherapy in Ph+ ALL: the GIMEMA ALL2820 trial 4:52
Ponatinib plus blinatumomab versus imatinib and chemotherapy in Ph+ ALL: the GIMEMA ALL2820 trial
Sabina Chiaretti • 5 Dec 2025
Predictors of outcomes with and without alloSCT after first salvage therapy for R/R B-ALL 2:17
Predictors of outcomes with and without alloSCT after first salvage therapy for R/R B-ALL
Nicholas Short • 6 Dec 2025
Results from PARADIGM: aza-ven versus conventional chemo for newly diagnosed fit adults with AML 5:37
Results from PARADIGM: aza-ven versus conventional chemo for newly diagnosed fit adults with AML
Amir Fathi • 7 Dec 2025
The content of VJHemOnc is intended for healthcare professionals